When was Xencor founded?

Xencor was founded in 1997 and raised its 1st funding round 12 years after it was founded.

Where is Xencor located?

Xencor is headquartered in Monrovia, United States. It is registered at Monrovia, California.

How many employees does Xencor have?

As of Jul 31, 2026, the latest employee count at Xencor is 306.

Is Xencor a funded company?

Xencor is a funded company, having raised a total of $7.6M across 3 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Apr 10, 2009.

When was the latest funding round of Xencor?

Xencor's latest funding was a $***** Series A round on Jun 28, 2013, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $3.79B in funding in 2026 to date.

What is the annual revenue of Xencor?

Annual revenue of Xencor is between $100M and $500M as on Dec 31, 2025

Where does Xencor rank among its competitors?

Xencor ranks 90th amongst 5165 active competitors, of which 1218 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Xencor?

Xencor's top competitors include AbbVie, Jazz Pharmaceuticals and Gilead. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Xencor - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Xencor is developing superior monoclonal antibody therapeutics optimized to treat autoimmune disorders, asthma and allergic diseases, and cancer. Its antibody engineering platform precisely alters the Fc domain (the stem of the antibody structure) to significantly enhance natural functions and performance. Its product pipeline includes XmAb5871, a monoclonal antibody that targets CD19 with its variable domain and uses the XmAb immune inhibitory Fc domain to target FcγRIIb, a receptor that inhibits B cell function current in Phase 2 for the treatment of rheumatoid arthritis and lupus XmAb7195 for Asthma/Allergy. Also, have preclinical stage antibodies for the treatment of different cancers.

Website: xencor.com
Social
Registered Address: Monrovia, California

Key Metrics

Founded Year

1997

Location

Monrovia, United States

Stage

Public

Total Funding

$7.6M in 3 rounds

Latest Funding Round

Series A, Jun 28, 2013, $*****

Investors

Amgen Business Development & 4 more

Ranked

90^th among 5165 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

306 as on Jul 31, 2026

Investment & Acquisitions

Zenas BioPharma

Similar Companies

BeiGene & 647 more

Exit Details

Public

View Xencor's full profile

Xencor is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Xencor, Inc. CIN: 201622502 , United States, Active	Dec 26, 999	-	250 (As on Dec 31, 2024)	-
XENCOR INC CIN: 1326732 , United States, Active	Jun 07, 2004	$100M - $500M (As on Dec 31, 2025)	281 (As on Dec 31, 2022)	-

Xencor got listed on Dec 03, 2013.

Click here to take a look at Xencor's IPO in detail

Xencor has raised a total funding of $7.6M over 3 rounds. Its first funding round was on Apr 10, 2009. Xencor has 5 institutional investors.

Here is the list of recent funding rounds of Xencor:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 28, 2013	2456280	Series A	4675084	6673084	1648254	1295205
Dec 22, 2010	5644834	Conventional Debt	7235680	1496791	9377054	4349706
Apr 10, 2009	7258782	Conventional Debt	2446774	9040521	4963842	8881231

Access funding benchmarks and valuations. Sign up today!

View details of Xencor's funding rounds and investors

Xencor's employee count trend

Xencor has 306 employees as of Jul 26. Here is Xencor's employee count trend over the years:

Uncover Xencor's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Xencor include AbbVie, Jazz Pharmaceuticals and Gilead. Here is the list of Top 10 competitors of Xencor, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Pasadena Private Wealth, Berkshire Hathaway ... & 9 others	83/100
2nd	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	Quantinno, Iron Financial & 17 others	81/100
4th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Zhongguancun Development Group ... & 13 others	81/100
5th	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	79/100
6th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	76/100
7th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
8th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Perkins Wolf & Mc Donnell, Western Technology Investment ... & 16 others	74/100
9th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
10th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
90th	Xencor 1997, Monrovia (United States), Public	Engineering Antibodies to treat autoimmune disorders, asthma, allergic diseases and cancer	$7.6M	Amgen Business Development, Foresite Capital ... & 3 others	64/100